Jukka Westermarck
MD, PhD
jukka.westermarck@utu.fi +358 29 450 2880 +358 40 742 3007 Tykistökatu 6 Turku Office: 4124 (B-stairs, 4th floor) ORCID identifier: https://orcid.org/0000-0001-7478-3018 |
Role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers
Jukka Westermarck is a Professor of Cancer Biology, and Research Director, in the Turku Bioscience Centre at University of Turku.
Westermarck earned his medical degree from University of Turku in 1996. Two years later he obtained his PhD degree in Department of Medical Biochemistry and Department of Dermatology at the same University. He was working as a postdoctoral fellow in the laboratory of Dirk Bohmann during 1999-2001 in the European Molecular Biology Laboratory in Heidelberg, Germany. After being appointed as Academy Fellow by the Academy of Finland, he established his own research group at Turku Centre for Biotechnology in 2002. In 2006-2009 he was appointed as a group leader in the Institute of Medical Technology at University of Tampere, and after that he returned back to Turku due to his appointment as a tenure Research Director of Turku Centre for Biotechnology, and as a Professor of Cancer Biology at the Faculty of Medicine. In 2012, he worked as a visiting Professor at Dana-Farber Cancer Institute, Boston.
Professor Westermarck received young researcher prize from Finnish Medical Association Duodecim 2007, and Anders Jahre young investigator prize 2009 from University of Oslo, Norway. In 2017, he became an elected member of the Finnish Academy of Science and Letters.
Prof. Westermarck´s research focuses on role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers. Based on this work his group has identified several novel signaling principles how PP2A regulates cancer progression, as well as potential novel cancer therapy targets and diagnostic biomarkers.
- Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy Target (2013)
- Cancer Research
(A2 Refereed review article in a scientific journal ) - Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells (2013)
- Cancer Research
(A1 Refereed original research article in a scientific journal) - Identification of protein interactions involved in cellular signaling (2013)
- Molecular and Cellular Proteomics
(A2 Refereed review article in a scientific journal ) - Novel molecular markers for acute myeloid leukaemia disease activity (2013)
- European Journal of Cancer
(Other publication) - Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1 (2013)
- Cancer Discovery
(A1 Refereed original research article in a scientific journal) - CIP2A Promotes Proliferation of Spermatogonial Progenitor Cells and Spermatogenesis in Mice (2012)
- PLoS ONE
(A1 Refereed original research article in a scientific journal) - CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes (2012)
- Oncogene
(A1 Refereed original research article in a scientific journal) - Identification and Regulation of a Stage-Specific Stem Cell Niche Enriched by Nanog-Positive Spermatogonial Stem Cells in the Mouse Testis (2012)
- STEM CELLS
(A1 Refereed original research article in a scientific journal) - Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. (2012)
- Oncogene
(A1 Refereed original research article in a scientific journal) - Nucleolar AATF regulates c-Jun-mediated apoptosis (2012)
- Molecular Biology of the Cell
(A1 Refereed original research article in a scientific journal)



